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The processing pathway of prelamin A 
M. Sinensky1, K. Fantle1, M. Trujillo1, T. McLain1, A. Kupfer2 and M. Dalton1 
1Eleanor Roosevelt Institute, Denver, CO 80206, USA 
2Division of Basic Sciences, National Jewish Center for Immunology, Denver, CO 80206, USA 
SUMMARY 
The conversion of mammalian prelamin A to mature lamin 
A proceeds through the removal of 18 amino acids from the 
carboxyl terminus. The initial step in this processing is the 
isoprenylation of a CAAX box cysteine. This proteolytic 
event is distinctive for prelamin A among the known preny­
lated mammalian proteins. Since the carboxyl terminus of 
prelamin A is removed during maturation, it is not obvious 
that this protein would undergo the two reactions subse­
quent to prenylation observed in other CAAX box proteins 
- the endoproteolytic removal of the carboxyl-terminal 3 
amino acids and the subsequent methylation of the now 
carboxyl-terminal cysteine. 
To characterize the maturation of prelamin A further, 
we have developed a CHO-K1 cell line that possesses a dex­
amethasone-inducible human prelamin A against a genetic 
background of high mevalonate uptake. Utilizing this cell 
line in association with antibodies specific to the transgenic 
prelamin A, we have been able to demonstrate directly in 
vivo that prelamin A undergoes farnesylation and car­
boxymethylation prior to conversion to lamin A, as is the 
case for other prenylated proteins. We have demonstrated 
previously that in the absence of isoprenylation, conversion 
of prelamin A to lamin A is blocked, but that unprocessed 
prelamin A is transported to the nucleus where it can still 
undergo maturation. Consistent with the implications of 
these prior studies, we now demonstrate the presence of 
both subunits of farnesyl-protein transferase in the 
nucleus. 
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INTRODUCTION 
A number of mammalian proteins have been demonstrated to 
be post-translationally modified by a farnesyl residue in 
thioether linkage to a carboxyl-terminal cysteine (Sinensky and 
Lutz, 1992; Cox and Der, 1992). This modification occurs on 
the cysteine of proteins terminating in a so-called CAAX box 
in which A is an aliphatic amino acid and X is generally S, M, 
C, A, or Q. In three well described examples - p21ras (Hancock 
et al., 1989), γ -transducin (Fukada et al., 1990) and lamin B 
(Farnsworth et al., 1989; Sobotka-Briner and Chelsky, 1992) ­
farnesylation is the first of three sequential post-translational 
modifications that also include an endoproteolytic removal of 
the AAX tripeptide and subsequent methylation of the now 
carboxyl-terminal cysteine. Enzymes that catalyze all three of 
these steps have been characterized in vitro and have been 
reported to be cytosolic (Reiss et al., 1992; Ashby et al., 1992; 
Ma and Rando, 1992; Stephenson and Clarke, 1990). 
Prior studies from our laboratory have demonstrated that in 
some respects the precursor of the nuclear lamin A protein, 
prelamin A, is a novel prenylated protein. We have found sug­
gestive evidence that prelamin A undergoes its post-transla­
tional processing in the nucleus rather than in the cytosol (Lutz 
et al., 1992). Furthermore, in contrast to other mammalian 
prenylated proteins, prelamin A undergoes a proteolytic 
removal of the peptide domain bearing the prenyl group during 
its maturation to prelamin A (Weber et al., 1989; Beck et al., 
1990). For this reason, it has heretofore not been possible to 
determine experimentally whether prelamin A undergoes a 
processing pathway comparable to that seen for other preny­
lated proteins. Indeed, although both the sequence of the 
prelamin A CAAX box (CSIM) and assignment of prenylation 
by farnesyl in vitro (Lutz et al., 1992) would argue that 
prelamin A is farnesylated, it has not been previously possible 
to definitively demonstrate farnesylation of prelamin A in vivo. 
In this manuscript, we utilize a cell line bearing an inducible 
human prelamin A to characterize the processing pathway for 
this molecule in more detail and in vivo for the first time. 
Although the carboxyl terminus of prelamin A is removed 
during conversion of this molecule to lamin A, we demonstrate 
that its carboxyl-terminal processing is similar to that of other 
farnesylated proteins. We predict that this series of reactions 
would result in the production of a short farnesylated peptide 
reminiscent of fungal mating factors. Suggestive evidence is 
presented that this pathway may be unique, in mammalian 
cells, to prelamin A. 
MATERIALS AND METHODS 
Cells, plasmids and transfection 
The pMMLA construct, derived from the previously described 
pSP64-MMTV vector (Lutz et al., 1992), bears the cDNA for human 
prelamin A under control of a dexamethasone-inducible (MMTV) 
promotor. Human prelamin A cDNA cloned into pUC19 (Fisher et 
al., 1986), a kind gift from Dr N. Chaudhary (Rockefeller University), 
was excised by digestion with EcoRI and BamHI. This sequence was 
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inserted into pSP64-MMTV (Sarria et al., 1990) between its XbaI and 
BamHI sites. 
The recipient cell used for transfection with this construct was the 
CHO-K1-derived met-18b2 cell line (Faust and Krieger, 1987), which 
expresses a mevalonate transporter (Kim et al., 1992). Cells were 
transfected by the Lipofectin method, as described by the manufac­
turer (Gibco/BRL). Stable transfectants expressing human prelamin 
A were selected for G418 (Sigma) resistance after co-transfection 
with pSV2-neo (Southern and Berg, 1982) and then screening of indi­
vidual clones by indirect immunofluorescence with human species-
specific antibody (Loewinger and McKeon, 1988). A high expressor 
(MMLA) was chosen for further study. Optimal induction of lamin A 
expression was obtained by treatment of the MMLA cells with 10− 7 
M dexamethasone. 
Rat 2 cells are a rat fibroblast line (ATCC CRL1764) and were a 
kind gift from Dr Steven Nordeen (University of Colorado Health 
Sciences Center). 
All cells were grown in Ham’s F12 supplemented with 5% fetal 
calf serum. 
Indirect immunofluorescence 
Cells, plated on glass coverslips, are rinsed with phosphate buffered 
saline (PBS) and then fixed with 3% formaldehyde in PBS for 15 
minutes at − 20°C. Following two washes in 5 mM NH4Cl in PBS, the 
cells are permeablized to antibody with 0.05% Triton X-100 in PBS 
for 10 minutes at − 20°C. 
Antibodies and their dilutions for immunofluorescence were: 1E4 
(Loewinger and McKeon, 1988), an anti-human lamin A(1/1000), a 
kind gift from Dr Frank McKeon (Harvard University); bovine 
farnesyl-protein transferase α (1/50) and β (1/100) subunit antibodies 
(Omer et al., 1993), kind gifts from Drs C. Omer and J. Gibbs (Merck, 
Sharp and Dohme), rat farnesyl-protein transferase α -subunit 
antibody (1/50), a kind gift from Dr M. Brown (Southwestern Medical 
Center) (Reiss et al., 1991). 
Secondary antibodies were, for 1E4, rhodamine-conjugated sheep 
anti-mouse, diluted 1/25 (Cappel Laboratories); for farnesyl-protein 
transferase antibodies, rhodamine-conjugated goat anti-rabbit, diluted 
1/200 (Biomeda). 
Radioimmune precipitations 
Antibodies used were 1E4 (1:500 dilution) for A-lamins, an anti-lamin 
B rabbit antiserum (1:100 dilution) (a kind gift from Dr Nilabh 
Chaudhary) (Cance et al., 1992), and a rabbit polyclonal anti-human 
prelamin A-specific antiserum (1:200 dilution) that was generated 
against the prelamin A-specific peptide CLLGNSSPRTQSPQN and 
that will be described in detail elsewhere. It’s suitability for specific 
radio-immunoprecipitation of prelamin A is shown in Fig. 8C. 
MMLA cells (1× 107/100 mm Petri dish) were labeled either 
overnight with [methyl-3H]methionine (100 µ Ci/ml, specific activity 
85 Ci/mmol; Amersham) or 6 hours with [35S]methionine (100 
µ Ci/ml, specific activity �1000 Ci/mmol; DuPont-New England 
Nuclear) or for 2 hours with 5-R,S-[3H]mevalonate (200 µ Ci/ml, 
specific activity 30 Ci/mmol; American Radiochemical). MMLA cells 
were treated with lovastatin (8 µ g/ml) during mevalonate labeling. 
Radioactive lamin proteins were bound to anti-lamin antibodies by 
incubation, with shaking, overnight at 4°C, precipitated by means of 
Protein A/Sepharose beads and analyzed by SDS-PAGE as previously 
described (Beck et al., 1990). 
Base release assay 
After visualization of the proteins of interest by fluorography, the cor­
responding bands were cut out of the dried gel and placed into 0.5 ml 
microfuge tubes and rehydrated with 100 µ l of distilled water. Then 
200 µ l of 1.0 M NaOH was added to the tubes, which were then 
incubated at 37°C for 24 hours in capped, parafilm-sealed scintilla­
tion vials containing 2.5 ml of scintillation fluid. The tubes were 
removed and the base-releasable counts, which derive from methy­
lated carboxyl groups (Chelsky et al., 1987), determined after addition 
of another 7.5 ml of scintillation fluid. The unreacted material was 
also determined by liquid scintillation counting. 
Assignment of prenyl substituent for prelamin A 
Immunoprecipitated [3H]mevalonate-labeled prelamin A was isolated 
by SDS-PAGE and subjected to Raney nickel reductive cleavage 
followed by gas-liquid radiochromatographic analysis as previously 
described (Lutz et al., 1992). 
RESULTS 
Dexamethasone-inducible over-expression of 
human prelamin A 
In order to analyze the pathway of prelamin A processing, we 
needed to create conditions in which the intermediates in this 
processing pathway accumulate to levels that permit biochem­
ical characterization. We attempted to over-express prelamin 
A by isolation of transfectants in which prelamin A transcrip­
tion was driven by the SV40 promotor, but were unsuccessful. 
Reasoning that such over-expression might be lethal, we chose 
to utilize expression of prelamin A under the control of the 
dexamethasone-inducible MMTV promotor. To do this, we 
prepared the construct pMMLA (see Materials and Methods) 
and isolated a stably transfected clone (MMLA) of met-18b-2 
cells, which could be demonstrated to express a dexametha­
sone-inducible human lamin A as indicated by radioimmuno­
precipitation (Fig. 1), immunoblot (Fig. 2) and immunofluo­
rescence (Fig. 3) with the human lamin A species-specific 
antibody 1E4. These results demonstrate that MMLA cells are 
inducible for the synthesis of human lamin A, which is 
processed and assembled correctly into the host cell lamina. 
The met-18b-2 cell line, derived from CHO-K1, was chosen 
because of its previously described high rate of mevalonate 
uptake - some 50-fold greater than wild-type cells (Faust and 
Krieger, 1987). Based on radioimmunoprecipitation studies, 
we estimate that MMLA cells have approximately a 4-fold 
elevated rate of synthesis of lamin A compared to the parental 
cell line (data not shown). 
kDa Fig. 1. Dexamethasone-inducible 
human lamin A synthesis in MMLA 
cells. MMLA cells were labeled for 6 
hours with [35S]methionine in the 
presence (1) or absence (2) of 10− 7 
dexamethasone and the incorporation 
into lamin A visualized by radio­
immunoprecipitation, SDS-PAGE 
and fluorography. 
Fig. 2. Immunoblot of human 
lamin A of MMLA cells. The 
molecular masses of human 
lamin A from HeLa cells (A) and 
MMLA cells are compared (B) 
by SDS-PAGE followed by 
antibody visualization. MMLA cells were treated with 
dexamethasone overnight. Blotting was with the 1E4 antibody. 
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Fig. 3. Dexamethasone-inducible lamin 
A of MMLA cells: immunofluorescence 
- human lamin A of MMLA cells is 
visualized in the absence (A) or 
presence (B) of 10− 7 M dexamethasone 
overnight. Phase-contrast images of 
these fields are below the 
immunofluorescent images. 
Fig. 4. Radio-immunoprecipitation of 
[3H]mevalonate-labeled human prelamin 
A from MMLA cells. The 
immunoprecipitated labeled prelamin A 
from MMLA cells (lane 2) is compared to 
35S-labeled lamin proteins (lane 1) 
immunoprecipitated from HeLa cells 
treated with lovastatin (5 µ g/ml). Prelamin 
A (Ao) and lamin C are indicated. 
Immunopreciptiations were with the 1E4 













Demonstration that prelamin A is farnesylated in 
MMLA cells 
The elevated expression and mevalonate uptake of MMLA 
cells make them good candidates for the definitive demonstra­
tion of the expected farnesylation of this protein. Radioim­
munoprecipitation of prelamin A from these cells after labeling 
with [3H]mevalonate for 2 hours gave rise to a band that co­
migrated with immunoprecipitated prelamin A from HeLa 
cells (Fig. 4). The time-course of mevalonate labeling of 
MMLA cells established that 2 hours was the optimum period 
Fig. 5. Prelamin A is farnesylated. The SDS-PAGE band arising 
from [3H]mevalonate-labeled prelamin A as shown in Fig. 4 was 
excised, rehydrated and removed from the gel by electroelution. The 
for the accumulation of mevalonate-labeled prelamin A (data 
not shown). 
After mevalonate labeling, immunoprecipitated prelamin A 
was isolated by SDS-PAGE, visualized by fluorography, elec­
troeluted from the rehydrated gel and the isoprenoid substituent 
assigned by in-line radio-gas liquid chromatography. The 
results (Fig. 5) clearly demonstrate that prelamin A is farne­
sylated as would be expected from the sequence of the CAAX 
prenyl substituent on prelamin A was removed by Raney nickel 
cleavage and identified by co-migration in radio-gas liquid 
chromatography with bona fide mass standards (F, farnesyl; GG, 
geranylgeranyl). 
box and is consistent with previous in vitro studies (Lutz et al., 
1992). 
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Farnesyl-protein transferase can be found in the 
nucleus of mammalian cells 
We have demonstrated previously that treatment of cells with 
lovastatin results in the accumulation of unprenylated prelamin 
A in the nucleus (Beck et al., 1990; Lutz et al., 1992). Relief 
of the lovastatin block resulted in the rapid conversion of the 
prelamin A to lamin A. These data argued that processing of 
prelamin A could occur in the nucleus. With the above demon­
stration that prelamin A is farnesylated, we would, therefore, 
predict that farnesyl-protein transferase can be found in the 
nucleus. 
We sought to test this hypothesis by indirect immunofluo­
rescence. We obtained antibodies to the α and β subunits from 
others and visualized the sub-cellular distribution of these 
proteins in 3T3 cells (Fig. 6A,B). We also visualized the dis­
tribution of the α subunit in Rat 2 fibroblasts (Fig. 7A), since 
we expected greater specificity in these cells as the α -subunit 
antibody was raised against the rat protein. To ensure that 
specific recognition of the α subunit was being observed in the 
Rat 2 cells, we determined that the antibody-binding to these 
cells was inhibited by recombinant human farnesyl-protein 
transferase (Fig. 7B). The addition of 100 µ g/ml of bovine 
A B 
Fig. 6. Presence of farnesyl 
transferase in the nucleus of 
3T3 cells. (A) visualization 
with antiserum against α ­
subunit; (B) visualization 
with antiserum against β ­
subunit. 
serum albumin during antibody-binding had no effect (data not 
shown). Presence of α -subunit in the nucleus of Rat 2 cells was 
also confirmed by confocal microscopy (Fig. 7C). The results 
demonstrate clearly the specific recognition of farnesyl-protein 
transferase in the nucleus as well as in the cytosol. The 
presence of the enzyme in the cytosol is expected since it has 
a number of cytosolic protein substrates, e.g. p21ras (Hancock 
et al., 1989), γ -transducin (Fukada et al., 1990), rhodopsin 
kinase (Inglese et al., 1992), and is found in 100,000 g super­
natants of cell-free homogenates (Reiss et al., 1991). 
Demonstration that prelamin A, but not lamin A, is 
carboxymethylated in MMLA cells 
Other well characterized farnesylated proteins such as p21ras 
(Casey et al., 1989; Hancock et al., 1991) and lamin B 
(Farnsworth et al., 1989; Sobotka-Briner and Chelsky, 1992) 
undergo endoproteolytic removal of the carboxy-terminal 3 
amino acids of the CAAX box followed by methyl esterifica­
tion of the now carboxy-terminal cysteine. Since in prelamin 
A processing the whole carboxy terminus of the protein is 
removed, it is not at all obvious that prelamin A would neces­
sarily undergo these intermediate steps during formation of 
C
 
Fig. 7. Presence of α -subunit of farnesyl transferase in the nucleus of Rat 2 cells. (A) Visualization with antiserum against α -subunit; (B) same 
as (A) with the addition of 100 µ g/ml of recombinant farnesyl transferase; (C) confocal image of a section through the nucleus of cells from the 
slide shown in (A). 
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mination of the counts incorporated as carboxymethyl ester. 
After completion of the decarboxylation reaction, the counts 
incorporated into the protein in non-base releasable form were 
determined by transfer of the reaction mix to a separate scin­
tillation vial. Since the amino acid sequences of lamin A, 
prelamin A and lamin B are known, the carboxymethylation 
can be normalized to the amount of each protein synthesized 
by correction for the number of methionines in each of these 
proteins. 
The results (Fig. 8B) confirm the carboxyl-terminal methyl­
ation of lamin B that has previously been well documented 
(Sobotka-Briner and Chelsky, 1992). The nearly 10-fold 
greater incorporation of 3H as base-releasable counts in 
prelamin A compared to lamin A strongly argues that prelamin 
A processing involves a terminally carboxymethylated inter­
mediate. Removal of the carboxyl terminus of prelamin A 
during its conversion to mature lamin A would result in the 
observed lack of carboxymethylation of mature lamin A - a 
result that has been reported previously (Chelsky et al., 1987). CThe lower level of carboxymethylation in prelamin A than in 
lamin B is probably due to the carboxymethylated prelamin A 






































of mature lamin A. The other intermediates would be recog­
nized by the prelamin A antibody and thus contribute protein 
counts but not methyl counts to the determination. The speci­
ficity of the prelamin A antibody for immunoprecipitation is 
demonstrated in Fig. 8C. Although the experiments in Fig. 8 
do not directly demonstrate the existence of a farnesylated, 
methylated intermediate in prelamin A maturation the presence 
of both of these modifications in prelamin A and their absence 
in mature lamin A strongly suggests that such an intermediate 
exists. 
DISCUSSION 
Our studies on the farnesylation-dependent processing of 
prelamin A indicate that the sequential modifications that this 
molecule undergoes are similar to those previously described 
for other farnesylated proteins with two notable exceptions: the 
processing events for prelamin A can take place entirely in the 
nucleus and the farnesylated, methylated cysteinyl carboxyl­
terminal peptide of the prelamin A molecule is removed from 
this protein. 
The presence in the nucleus of a key activity required for 
Fig. 8. Carboxymethylation of prelamin A. (A) After labeling of 
MMLA cells with [methyl-3H]methionine, prelamin A (lane 1), 
lamin A (lane 2) and lamin B (lane 3) are sequentially 
immunoprecipitated and isolated by SDS-PAGE. (B) Relative 
incorporation of label into carboxymethyl moieties is determined by 
base-release assay (see Materials and Methods). (C) Specificity of 
the prelamin A anti-sera in the immunoprecipitation of prelamin A in 
MMLA cells. The antiserum only immunoprecipitates a 74 kDa 
protein when prelamin A conversion to lamin A is blocked by 
lovastatin. Cells (4× 106/100 mm plate) were incubated overnight 
with 35 µ Ci/ml [35S]methionine (Trans-label, Amersham) and 10− 7 
M dexamethasone in the presence (+) or absence (− ) of 10 µ g/ml 
lovastatin. 
mature lamin A. To determine whether prelamin A becomes 
carboxymethylated during its conversion to mature lamin A, 
we utilized the following strategy. 
MMLA cells were induced with dexamethasone and 
incubated overnight with [methyl-3H]methionine. Tritium from 
this molecule has been well demonstrated to be incorporated 
into proteins either as methionine residues or, through metab­
olism to S-adenosyl methionine, into methyl substituents of 
carboxyl acceptors (Chelsky et al., 1987). To quantitatively 
determine carboxymethylation of prelamin A, we first sequen­
tially immunoprecipitated prelamin A, lamin A and lamin B 
with specific antibodies for each of these proteins and isolated 
them by SDS-PAGE, followed by fluorographic visualization 
(Fig. 8A). Regions of the dried gel bearing these proteins were 
excised, re-hydrated and treated with base for vapor-phase 
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prelamin A processing - the farnesyl-protein transferase - is 
consistent with studies that we have previously reported (Lutz 
et al., 1992) as well as studies of lamin carboxymethylation 
(Sobotka-Briner and Chelsky, 1992). Also consistent with 
nuclear localization of prelamin A processing is a recent report 
that microinjected prelamin A localizes to the nucleoplasm 
prior to assembly into the lamina (Goldman et al., 1992). We 
have obtained similar results by immunofluorescent localiza­
tion of non-farnesylated prelamin A and have argued that the 
proteolytic removal of the prelamin A carboxyl terminus is 
required for assembly of lamin A into the lamina (Lutz et al., 
1992). We have not yet determined whether B-lamins, which 
also undergo farnesylation-dependent carboxyl-terminal pro­
cessing (but retain the modified cysteine in the mature protein) 
are also farnesylated in the nucleus, but this would seem likely. 
The presence of farnesyl-protein transferase in the 
mammalian cell nucleus immediately raises the question of the 
mechanism of its localization to that organelle. There is no 
obvious nuclear localization signal, of the polybasic SV40 T 
antigen type, in the published sequences of either the α or β 
subunits of this enzyme (Omer et al., 1993). Current models of 
nuclear transport require the presence of such a signal or the 
binding to another protein with a nuclear localization signal to 
permit uptake. Perhaps farnesyl-protein transferase can bind 
such a transporter peptide, or perhaps it possesses a distinct 
mechanism to facilitate the nuclear uptake. Binding to a trans­
porter peptide could explain the dual localization of the 
farnesyl-protein transferase in cytosol and nuclei, since such a 
mechanism could result in equilibration of proteins across the 
nuclear membrane. Proteins possessing a nuclear localization 
signal not only exhibit enhanced uptake into the nucleus, but 
also accumulate to much higher levels there relative to other 
cellular compartments. Whatever mechanism exists for 
transport must also permit the observed distribution of this 
enzyme in cytosol as well as nuclei. 
An attractive hypothesis is that the nuclear farnesyl-protein 
transferase is in some way chemically distinct from the 
cytosolic enzyme. Preliminary studies comparing the sensitiv­
ity of Triton-X-100-soluble proteins versus Triton-insoluble 
proteins to farnesyl-protein transferase inhibitors (James et al., 
1993) suggests that farnesylation of the soluble proteins is dif­
ferentially sensitive to benzodiazopine peptidomimetics. Since 
the major Triton-insoluble proteins are those of the nuclear 
lamina, this finding, if borne out by more complete studies, 
would be consistent with a chemical difference between the 
cytosolic and nuclear farnesyl-protein transferase. 
Given that the end result of prelamin A processing is a 
protein missing its carboxyl-terminal 18 amino acids, it is not 
obvious that the maturation of this molecule would proceed 
through a carboxymethylated cysteine intermediate. Highly 
analogous farnesylation-dependent processing pathways are 
well described for certain fungal peptides, which act as mating 
factors. The most similar situation to that seen for prelamin A 
is the mating factor of the basidomycete Tremella mesenter­
ica, which arises from a 26 kDa precursor protein by carboxyl­
terminal modification and subsequent endoproteolytic release 
of the 2 kDa biologically active farnesylated peptide 
(Miyakawa et al., 1985). 
The demonstration of a carboxymethylated farnesylated 
cysteinyl intermediate in prelamin A maturation is also highly 
similar to the steps involved in the maturation of Saccha­
romyces cerevisiae mating pheromone a-factor (Marcus et al., 
1990). This peptide pheromone also terminates in a farnesy­
lated, carboxymethylated cysteine and is generated from a 
larger precursor peptide by an endoproteolytic clip. It has 
recently been reported (Chen et al., 1992) that the endoprote­
olytic reaction that is required for a-factor maturation is 
sensitive to mutations in the precursor peptide, which flank the 
junction of the amino-terminal extension and mature a-factor. 
This result suggests that the endoprotease involved in a-factor 
maturation recognizes a sequence of amino acid residues 
around the cleavage site. If a similar endoproteolytic 
mechanism were operative in the case of prelamin A, it might 
be expected that an unusual and conserved amino acid 
sequence might be found in prelamin A flanking the lamin A 
carboxyl terminus. Computer data base searches reveal that the 
hexapeptide sequence flanking the putative endoproteolysis 
site (RSYfLLG) is unique to prelamin A in the current protein 
sequence data base, as well as being highly conserved across 
species. This sequence, therefore, stands as a candidate for the 
recognition site of a prelamin A-specific endoprotease. 
This work was supported by ACS grant BE-29F for M.S. and NIH 
grant AI 23764 for A.K. 
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